Literature DB >> 26416328

Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned.

David J Back1, David M Burger2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26416328     DOI： 10.1053/j.gastro.2015.09.031

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  20 in total

1.  Viral hepatitis: Drug-drug interactions in HCV treatment--the good, the bad and the ugly.

Authors:  Jacob A Langness; Gregory T Everson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-17       Impact factor: 46.802

2.  New Therapies for Hepatitis C Virus Infection.

Authors:  Jennifer L Horsley-Silva; Hugo E Vargas
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-01

Review 3.  Genotype 3 Infection: The Last Stand of Hepatitis C Virus.

Authors:  Austin Chan; Keyur Patel; Susanna Naggie
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

4.  Pharmacist-led pre-treatment assessment, management and outcomes in a Hepatitis C treatment patient cohort.

Authors:  Miriam Coghlan; Aisling O'Leary; Gail Melanophy; Colm Bergin; Suzanne Norris
Journal:  Int J Clin Pharm       Date:  2019-07-11

5.  Bradyarrhythmia induced by amiodarone-sofosbuvir co-administration.

Authors:  Mohammed El Amine Ghembaza; Ali Lounici
Journal:  Indian J Gastroenterol       Date:  2016-07

Review 6.  Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis.

Authors:  Daniel Caldeira; Filipe B Rodrigues; Marta M Duarte; Carmelo Sterrantino; Márcio Barra; Nilza Gonçalves; Fausto J Pinto; Joaquim J Ferreira; João Costa
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

Review 7.  Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms.

Authors:  Li Pang; Philip Sager; Xi Yang; Hong Shi; Frederick Sannajust; Mathew Brock; Joseph C Wu; Najah Abi-Gerges; Beverly Lyn-Cook; Brian R Berridge; Norman Stockbridge
Journal:  Circ Res       Date:  2019-10-10       Impact factor: 17.367

8.  The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions.

Authors:  Elise J Smolders; Floor Ac Berden; Clara Tmm de Kanter; Wietske Kievit; Joost Ph Drenth; David M Burger
Journal:  United European Gastroenterol J       Date:  2016-11-04       Impact factor: 4.623

Review 9.  Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.

Authors:  Sarah Talavera Pons; Anne Boyer; Geraldine Lamblin; Philip Chennell; François-Thibault Châtenet; Carine Nicolas; Valérie Sautou; Armand Abergel
Journal:  Br J Clin Pharmacol       Date:  2016-10-26       Impact factor: 4.335

Review 10.  Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.

Authors:  Christine E MacBrayne; Jennifer J Kiser
Journal:  Clin Infect Dis       Date:  2016-07-15       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.